Skip to main content
Top
Published in: BMC Immunology 1/2012

Open Access 01-12-2012 | Research article

Biodistribution and elimination kinetics of systemic Stx2 by the Stx2A and Stx2B subunit-specific human monoclonal antibodies in mice

Authors: Abhineet Sheoran, Kwang-il Jeong, Jean Mukherjee, Anthony Wiffin, Pradeep Singh, Saul Tzipori

Published in: BMC Immunology | Issue 1/2012

Login to get access

Abstract

Background

Hemolytic uremic syndrome (HUS) leading to acute kidney failure, is a condition linked to the production of primarily Shiga toxin 2 (Stx2) by some E. coli serotypes. We have previously shown that Stx2 A subunit-specific human monoclonal antibody (HuMAb) 5C12, and B subunit-specific HuMAb 5H8 inhibit cultured cell death, and protect mice and piglets from fatal Stx2-intoxication. We have also shown that 5H8 blocks binding of Stx2 to its cell-surface receptor globotriaosyl ceramide (Gb3), whereas Stx2 when complexed with 5C12 binds Gb3 with higher affinity than Stx2. The mechanism by which 5C12 neutralizes Stx2 in vitro involves trapping of Stx2 in the recycling endosomes and releasing it into the extracellular environment. Because of the clinical implications associated with the formation of Stx2/antibody complexes and the potential for trapping and clearance through a severely damaged kidney associated with HUS, we investigated the likely site(s) of Stx2/antibody localization and clearance in intoxicated mice treated with antibody or placebo.

Results

Mice were injected with radiolabeled Stx2 (125I-Stx2) 4 hours after administration of 5C12, 5H8, or phosphate buffered saline (PBS) and the sites of localization of labeled Stx2, were investigated 3, 24 and 48 hours later. The liver recorded statistically much higher concentrations of labeled Stx2 for groups receiving 5C12 and 5H8 antibodies after 3, 24 and 48 hours, as compared with the PBS group. In contrast, highest levels of labeled Stx2 were detected in the kidneys of the PBS group at all 3 sampling times. Mice receiving either of the two HuMAbs were fully protected against the lethal effect of Stx2, as compared with the fatal outcome of the control group.

Conclusions

The results suggest that HuMAbs 5C12 and 5H8 promoted hepatic accumulation and presumably clearance of toxin/antibody complexes, significantly diverting Stx2 localization in the kidneys, the target of Stx2 and the cause of HUS. This is in contrast to the fatal outcome of the control group receiving PBS. The results also confirm earlier observations that both HuMAbs are highly and equally protective against Stx2 intoxication in mice.
Appendix
Available only for authorised users
Literature
1.
go back to reference Boerlin P, McEwen SA, Boerlin-Petzold F, Wilson JB, Johnson RP, Gyles CL: Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J Clin Microbiol. 1999, 37: 497-503.PubMedPubMedCentral Boerlin P, McEwen SA, Boerlin-Petzold F, Wilson JB, Johnson RP, Gyles CL: Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J Clin Microbiol. 1999, 37: 497-503.PubMedPubMedCentral
2.
go back to reference Griffin PM, Tauxe RV: The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol Rev. 1991, 13: 60-98.PubMed Griffin PM, Tauxe RV: The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol Rev. 1991, 13: 60-98.PubMed
3.
go back to reference Milford DV, Taylor CM, Guttridge B, Hall SM, Rowe B, Kleanthous H: Haemolytic uraemic syndromes in the British Isles 1985–8: association with verocytotoxin producing Escherichia coli. Part 1: Clinical and epidemiological aspects. Arch Dis Child. 1990, 65: 716-721. 10.1136/adc.65.7.716.PubMedPubMedCentralCrossRef Milford DV, Taylor CM, Guttridge B, Hall SM, Rowe B, Kleanthous H: Haemolytic uraemic syndromes in the British Isles 1985–8: association with verocytotoxin producing Escherichia coli. Part 1: Clinical and epidemiological aspects. Arch Dis Child. 1990, 65: 716-721. 10.1136/adc.65.7.716.PubMedPubMedCentralCrossRef
4.
go back to reference Ostroff SM, Tarr PI, Neill MA, Lewis JH, Hargrett-Bean N, Kobayashi JM: Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis. 1989, 160: 994-998. 10.1093/infdis/160.6.994.PubMedCrossRef Ostroff SM, Tarr PI, Neill MA, Lewis JH, Hargrett-Bean N, Kobayashi JM: Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis. 1989, 160: 994-998. 10.1093/infdis/160.6.994.PubMedCrossRef
5.
go back to reference Fraser ME, Fujinaga M, Cherney MM, Melton-Celsa AR, Twiddy EM, O'Brien AD, James MN: Structure of shiga toxin type 2 (Stx2) from escherichia coli O157:H7. J Biol Chem. 2004, 279: 27511-27517. 10.1074/jbc.M401939200.PubMedCrossRef Fraser ME, Fujinaga M, Cherney MM, Melton-Celsa AR, Twiddy EM, O'Brien AD, James MN: Structure of shiga toxin type 2 (Stx2) from escherichia coli O157:H7. J Biol Chem. 2004, 279: 27511-27517. 10.1074/jbc.M401939200.PubMedCrossRef
6.
go back to reference Friedrich AW, Bielaszewska M, Zhang WL, Pulz M, Kuczius T, Ammon A, Karch H: Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis. 2002, 185: 74-84. 10.1086/338115.PubMedCrossRef Friedrich AW, Bielaszewska M, Zhang WL, Pulz M, Kuczius T, Ammon A, Karch H: Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis. 2002, 185: 74-84. 10.1086/338115.PubMedCrossRef
7.
go back to reference Russmann H, Schmidt H, Heesemann J, Caprioli A, Karch H: Variants of Shiga-like toxin II constitute a major toxin component in Escherichia coli O157 strains from patients with haemolytic uraemic syndrome. J Med Microbiol. 1994, 40: 338-343. 10.1099/00222615-40-5-338.PubMedCrossRef Russmann H, Schmidt H, Heesemann J, Caprioli A, Karch H: Variants of Shiga-like toxin II constitute a major toxin component in Escherichia coli O157 strains from patients with haemolytic uraemic syndrome. J Med Microbiol. 1994, 40: 338-343. 10.1099/00222615-40-5-338.PubMedCrossRef
8.
go back to reference Tzipori S, Sheoran A, Akiyoshi D, Donohue-Rolfe A, Trachtman H: Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome. Clin Microbiol Rev. 2004, 17: 926-941. 10.1128/CMR.17.4.926-941.2004. table of contentsPubMedPubMedCentralCrossRef Tzipori S, Sheoran A, Akiyoshi D, Donohue-Rolfe A, Trachtman H: Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome. Clin Microbiol Rev. 2004, 17: 926-941. 10.1128/CMR.17.4.926-941.2004. table of contentsPubMedPubMedCentralCrossRef
9.
go back to reference Ling H, Boodhoo A, Hazes B, Cummings MD, Armstrong GD, Brunton JL, Read RJ: Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry. 1998, 37: 1777-1788. 10.1021/bi971806n.PubMedCrossRef Ling H, Boodhoo A, Hazes B, Cummings MD, Armstrong GD, Brunton JL, Read RJ: Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry. 1998, 37: 1777-1788. 10.1021/bi971806n.PubMedCrossRef
10.
go back to reference Shimizu H, Field RA, Homans SW, Donohue-Rolfe A: Solution structure of the complex between the B-subunit homopentamer of verotoxin VT-1 from Escherichia coli and the trisaccharide moiety of globotriaosylceramide. Biochemistry. 1998, 37: 11078-11082. 10.1021/bi980946+.PubMedCrossRef Shimizu H, Field RA, Homans SW, Donohue-Rolfe A: Solution structure of the complex between the B-subunit homopentamer of verotoxin VT-1 from Escherichia coli and the trisaccharide moiety of globotriaosylceramide. Biochemistry. 1998, 37: 11078-11082. 10.1021/bi980946+.PubMedCrossRef
11.
go back to reference Lingwood CA, Law H, Richardson S, Petric M, Brunton JL, De Grandis S, Karmali M: Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J Biol Chem. 1987, 262: 8834-8839.PubMed Lingwood CA, Law H, Richardson S, Petric M, Brunton JL, De Grandis S, Karmali M: Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J Biol Chem. 1987, 262: 8834-8839.PubMed
12.
go back to reference Waddell T, Head S, Petric M, Cohen A, Lingwood C: Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2. Biochem Biophys Res Commun. 1988, 152: 674-679. 10.1016/S0006-291X(88)80091-3.PubMedCrossRef Waddell T, Head S, Petric M, Cohen A, Lingwood C: Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2. Biochem Biophys Res Commun. 1988, 152: 674-679. 10.1016/S0006-291X(88)80091-3.PubMedCrossRef
13.
go back to reference Garred O, Dubinina E, Holm PK, Olsnes S, van Deurs B, Kozlov JV, Sandvig K: Role of processing and intracellular transport for optimal toxicity of Shiga toxin and toxin mutants. Exp Cell Res. 1995, 218: 39-49. 10.1006/excr.1995.1128.PubMedCrossRef Garred O, Dubinina E, Holm PK, Olsnes S, van Deurs B, Kozlov JV, Sandvig K: Role of processing and intracellular transport for optimal toxicity of Shiga toxin and toxin mutants. Exp Cell Res. 1995, 218: 39-49. 10.1006/excr.1995.1128.PubMedCrossRef
14.
go back to reference Sandvig K, van Deurs B: Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin. Physiol Rev. 1996, 76: 949-966.PubMed Sandvig K, van Deurs B: Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin. Physiol Rev. 1996, 76: 949-966.PubMed
15.
go back to reference Garred O, van Deurs B, Sandvig K: Furin-induced cleavage and activation of Shiga toxin. J Biol Chem. 1995, 270: 10817-10821. 10.1074/jbc.270.18.10817.PubMedCrossRef Garred O, van Deurs B, Sandvig K: Furin-induced cleavage and activation of Shiga toxin. J Biol Chem. 1995, 270: 10817-10821. 10.1074/jbc.270.18.10817.PubMedCrossRef
16.
go back to reference Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K: Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem. 1988, 171: 45-50. 10.1111/j.1432-1033.1988.tb13756.x.PubMedCrossRef Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K: Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem. 1988, 171: 45-50. 10.1111/j.1432-1033.1988.tb13756.x.PubMedCrossRef
17.
go back to reference Saxena SK, O'Brien AD, Ackerman EJ: Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28S RNA when microinjected into Xenopus oocytes. J Biol Chem. 1989, 264: 596-601.PubMed Saxena SK, O'Brien AD, Ackerman EJ: Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28S RNA when microinjected into Xenopus oocytes. J Biol Chem. 1989, 264: 596-601.PubMed
18.
go back to reference Mukherjee J, Chios K, Fishwild D, Hudson D, O'Donnell S, Rich SM, Donohue-Rolfe A, Tzipori S: Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect Immun. 2002, 70: 612-619. 10.1128/IAI.70.2.612-619.2002.PubMedPubMedCentralCrossRef Mukherjee J, Chios K, Fishwild D, Hudson D, O'Donnell S, Rich SM, Donohue-Rolfe A, Tzipori S: Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect Immun. 2002, 70: 612-619. 10.1128/IAI.70.2.612-619.2002.PubMedPubMedCentralCrossRef
19.
go back to reference Mukherjee J, Chios K, Fishwild D, Hudson D, O'Donnell S, Rich SM, Donohue-Rolfe A, Tzipori S: Production and characterization of protective human antibodies against Shiga toxin 1. Infect Immun. 2002, 70: 5896-5899. 10.1128/IAI.70.10.5896-5899.2002.PubMedPubMedCentralCrossRef Mukherjee J, Chios K, Fishwild D, Hudson D, O'Donnell S, Rich SM, Donohue-Rolfe A, Tzipori S: Production and characterization of protective human antibodies against Shiga toxin 1. Infect Immun. 2002, 70: 5896-5899. 10.1128/IAI.70.10.5896-5899.2002.PubMedPubMedCentralCrossRef
20.
go back to reference Sheoran AS, Chapman S, Singh P, Donohue-Rolfe A, Tzipori S: Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants. Infect Immun. 2003, 71: 3125-3130. 10.1128/IAI.71.6.3125-3130.2003.PubMedPubMedCentralCrossRef Sheoran AS, Chapman S, Singh P, Donohue-Rolfe A, Tzipori S: Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants. Infect Immun. 2003, 71: 3125-3130. 10.1128/IAI.71.6.3125-3130.2003.PubMedPubMedCentralCrossRef
21.
go back to reference Sheoran AS, Chapman-Bonofiglio S, Harvey BR, Mukherjee J, Georgiou G, Donohue-Rolfe A, Tzipori S: Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect Immun. 2005, 73: 4607-4613. 10.1128/IAI.73.8.4607-4613.2005.PubMedPubMedCentralCrossRef Sheoran AS, Chapman-Bonofiglio S, Harvey BR, Mukherjee J, Georgiou G, Donohue-Rolfe A, Tzipori S: Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect Immun. 2005, 73: 4607-4613. 10.1128/IAI.73.8.4607-4613.2005.PubMedPubMedCentralCrossRef
22.
go back to reference Psotka MA, Obata F, Kolling GL, Gross LK, Saleem MA, Satchell SC, Mathieson PW, Obrig TG: Shiga toxin 2 targets the murine renal collecting duct epithelium. Infect Immun. 2009, 77: 959-969. 10.1128/IAI.00679-08.PubMedPubMedCentralCrossRef Psotka MA, Obata F, Kolling GL, Gross LK, Saleem MA, Satchell SC, Mathieson PW, Obrig TG: Shiga toxin 2 targets the murine renal collecting duct epithelium. Infect Immun. 2009, 77: 959-969. 10.1128/IAI.00679-08.PubMedPubMedCentralCrossRef
23.
go back to reference Donohue-Rolfe A, Acheson DW, Kane AV, Keusch GT: Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies. Infect Immun. 1989, 57: 3888-3893.PubMedPubMedCentral Donohue-Rolfe A, Acheson DW, Kane AV, Keusch GT: Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies. Infect Immun. 1989, 57: 3888-3893.PubMedPubMedCentral
24.
go back to reference Hunter WM, Greenwood FC: Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 1962, 194: 495-496. 10.1038/194495a0.PubMedCrossRef Hunter WM, Greenwood FC: Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 1962, 194: 495-496. 10.1038/194495a0.PubMedCrossRef
25.
go back to reference Fuchs G, Mobassaleh M, Donohue-Rolfe A, Montgomery RK, Grand RJ, Keusch GT: Pathogenesis of Shigella diarrhea: rabbit intestinal cell microvillus membrane binding site for Shigella toxin. Infect Immun. 1986, 53: 372-377.PubMedPubMedCentral Fuchs G, Mobassaleh M, Donohue-Rolfe A, Montgomery RK, Grand RJ, Keusch GT: Pathogenesis of Shigella diarrhea: rabbit intestinal cell microvillus membrane binding site for Shigella toxin. Infect Immun. 1986, 53: 372-377.PubMedPubMedCentral
26.
go back to reference Davies KA, Robson MG, Peters AM, Norsworthy P, Nash JT, Walport MJ: Defective Fc-dependent processing of immune complexes in patients with systemic lupus erythematosus. Arthritis Rheum. 2002, 46: 1028-1038. 10.1002/art.10189.PubMedCrossRef Davies KA, Robson MG, Peters AM, Norsworthy P, Nash JT, Walport MJ: Defective Fc-dependent processing of immune complexes in patients with systemic lupus erythematosus. Arthritis Rheum. 2002, 46: 1028-1038. 10.1002/art.10189.PubMedCrossRef
27.
go back to reference Johansson AG, Lovdal T, Magnusson KE, Berg T, Skogh T: Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats. Hepatology. 1996, 24: 169-175.PubMed Johansson AG, Lovdal T, Magnusson KE, Berg T, Skogh T: Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats. Hepatology. 1996, 24: 169-175.PubMed
28.
go back to reference Lovdal T, Andersen E, Brech A, Berg T: Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver. J Cell Sci. 2000, 113 (Pt 18): 3255-3266.PubMed Lovdal T, Andersen E, Brech A, Berg T: Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver. J Cell Sci. 2000, 113 (Pt 18): 3255-3266.PubMed
29.
go back to reference Obata F, Tohyama K, Bonev AD, Kolling GL, Keepers TR, Gross LK, Nelson MT, Sato S, Obrig TG: Shiga toxin 2 affects the central nervous system through receptor globotriaosylceramide localized to neurons. J Infect Dis. 2008, 198: 1398-1406. 10.1086/591911.PubMedPubMedCentralCrossRef Obata F, Tohyama K, Bonev AD, Kolling GL, Keepers TR, Gross LK, Nelson MT, Sato S, Obrig TG: Shiga toxin 2 affects the central nervous system through receptor globotriaosylceramide localized to neurons. J Infect Dis. 2008, 198: 1398-1406. 10.1086/591911.PubMedPubMedCentralCrossRef
30.
go back to reference Rutjes NW, Binnington BA, Smith CR, Maloney MD, Lingwood CA: Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Int. 2002, 62: 832-845. 10.1046/j.1523-1755.2002.00502.x.PubMedCrossRef Rutjes NW, Binnington BA, Smith CR, Maloney MD, Lingwood CA: Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Int. 2002, 62: 832-845. 10.1046/j.1523-1755.2002.00502.x.PubMedCrossRef
31.
go back to reference Shen DH, Kloos RT, Mazzaferri EL, Jhian SM: Sodium iodide symporter in health and disease. Thyroid. 2001, 11: 415-425. 10.1089/105072501300176372.PubMedCrossRef Shen DH, Kloos RT, Mazzaferri EL, Jhian SM: Sodium iodide symporter in health and disease. Thyroid. 2001, 11: 415-425. 10.1089/105072501300176372.PubMedCrossRef
32.
go back to reference Cohen A, Madrid-Marina V, Estrov Z, Freedman MH, Lingwood CA, Dosch HM: Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease. Int Immunol. 1990, 2: 1-8. 10.1093/intimm/2.1.1.PubMedCrossRef Cohen A, Madrid-Marina V, Estrov Z, Freedman MH, Lingwood CA, Dosch HM: Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease. Int Immunol. 1990, 2: 1-8. 10.1093/intimm/2.1.1.PubMedCrossRef
33.
go back to reference Menge C, Wieler LH, Schlapp T, Baljer G: Shiga toxin 1 from Escherichia coli blocks activation and proliferation of bovine lymphocyte subpopulations in vitro. Infect Immun. 1999, 67: 2209-2217.PubMedPubMedCentral Menge C, Wieler LH, Schlapp T, Baljer G: Shiga toxin 1 from Escherichia coli blocks activation and proliferation of bovine lymphocyte subpopulations in vitro. Infect Immun. 1999, 67: 2209-2217.PubMedPubMedCentral
34.
go back to reference Sugatani J, Igarashi T, Shimura M, Yamanaka T, Takeda T, Miwa M: Disorders in the immune responses of T- and B-cells in mice administered intravenous verotoxin 2. Life Sci. 2000, 67: 1059-1072. 10.1016/S0024-3205(00)00703-7.PubMedCrossRef Sugatani J, Igarashi T, Shimura M, Yamanaka T, Takeda T, Miwa M: Disorders in the immune responses of T- and B-cells in mice administered intravenous verotoxin 2. Life Sci. 2000, 67: 1059-1072. 10.1016/S0024-3205(00)00703-7.PubMedCrossRef
Metadata
Title
Biodistribution and elimination kinetics of systemic Stx2 by the Stx2A and Stx2B subunit-specific human monoclonal antibodies in mice
Authors
Abhineet Sheoran
Kwang-il Jeong
Jean Mukherjee
Anthony Wiffin
Pradeep Singh
Saul Tzipori
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2012
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/1471-2172-13-27

Other articles of this Issue 1/2012

BMC Immunology 1/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.